{"transactions":[{"id":867781,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T18:33:55.000Z","date":"2026-02-27","kind":"grant","planned":true,"acquired":true,"shares":5442,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F9","text":"The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027."}],"balance_after":5442,"derivative":{"underlying":"Common Stock","underlying_shares":5442},"source":{"system":"sec-edgar","filing":"0001801385-26-000002","document":"wk-form4_1772580832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138526000002/wk-form4_1772580832.xml","form_type":"4"}},{"id":867780,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T18:33:55.000Z","date":"2026-02-27","kind":"grant","planned":true,"acquired":true,"shares":13575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock options vest in four equal annual installments beginning on February 27, 2027."}],"balance_after":13575,"derivative":{"exercise_price":275.64,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":13575},"source":{"system":"sec-edgar","filing":"0001801385-26-000002","document":"wk-form4_1772580832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138526000002/wk-form4_1772580832.xml","form_type":"4"}},{"id":867779,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T18:33:55.000Z","date":"2026-02-27","kind":"exercise","planned":true,"acquired":false,"shares":550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"2,200 restricted stock units (\"RSUs\") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2,200 restricted stock units (\"RSUs\") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2,200 restricted stock units (\"RSUs\") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026."}],"balance_after":1650,"derivative":{"underlying":"Common Stock","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001801385-26-000002","document":"wk-form4_1772580832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138526000002/wk-form4_1772580832.xml","form_type":"4"}},{"id":867778,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Performance Stock Units","published_at":"2026-03-03T18:33:55.000Z","date":"2026-02-27","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"15,000 performance stock units (\"PSUs\") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"15,000 performance stock units (\"PSUs\") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"15,000 performance stock units (\"PSUs\") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001801385-26-000002","document":"wk-form4_1772580832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138526000002/wk-form4_1772580832.xml","form_type":"4"}},{"id":867777,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-03T18:33:55.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":750,"price":267.6,"value":200700.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan."}],"balance_after":22366,"source":{"system":"sec-edgar","filing":"0001801385-26-000002","document":"wk-form4_1772580832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138526000002/wk-form4_1772580832.xml","form_type":"4"}},{"id":867776,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-03T18:33:55.000Z","date":"2026-02-27","kind":"tax_withholding","planned":true,"acquired":false,"shares":240,"price":275.64,"value":66153.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market."}],"balance_after":23116,"source":{"system":"sec-edgar","filing":"0001801385-26-000002","document":"wk-form4_1772580832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138526000002/wk-form4_1772580832.xml","form_type":"4"}},{"id":867775,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-03T18:33:55.000Z","date":"2026-02-27","kind":"exercise","planned":true,"acquired":true,"shares":550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"2,200 restricted stock units (\"RSUs\") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026."}],"balance_after":23356,"source":{"system":"sec-edgar","filing":"0001801385-26-000002","document":"wk-form4_1772580832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138526000002/wk-form4_1772580832.xml","form_type":"4"}},{"id":867774,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-03T18:33:55.000Z","date":"2026-02-27","kind":"tax_withholding","planned":true,"acquired":false,"shares":3262,"price":275.64,"value":899137.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market."}],"balance_after":22806,"source":{"system":"sec-edgar","filing":"0001801385-26-000002","document":"wk-form4_1772580832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138526000002/wk-form4_1772580832.xml","form_type":"4"}},{"id":867773,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-03T18:33:55.000Z","date":"2026-02-27","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"15,000 performance stock units (\"PSUs\") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026."}],"balance_after":26068,"source":{"system":"sec-edgar","filing":"0001801385-26-000002","document":"wk-form4_1772580832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138526000002/wk-form4_1772580832.xml","form_type":"4"}},{"id":910024,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 6, 2025, and will terminate on August 31, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The options vested ratably over a four-year period beginning on February 28, 2022."}],"balance_after":12500,"derivative":{"exercise_price":63.55,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":910023,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"gift","planned":true,"acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents a bona fide gift of the Company's common stock to a charitable donor-advised fund."}],"balance_after":18568,"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":910022,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":96,"price":277.88,"value":26676.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The transaction was executed in a single trade."}],"balance_after":19318,"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":910021,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":400,"price":275.68,"value":110272.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades ranging from $275.445 to $275.930. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":19414,"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":910020,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":552,"price":274.6388,"value":151600.6176,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades ranging from $274.305 to $274.815. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":19814,"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":910019,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":928,"price":273.7075,"value":254000.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $273.160 to $274.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":20366,"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":910018,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":2824,"price":272.5079,"value":769562.3096,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $272.1275 to $273.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":21294,"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":910017,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":5700,"price":271.6627,"value":1548477.39,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades ranging from $271.105 to $272.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":24118,"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":910016,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":270.5579,"value":541115.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $270.010 to $270.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":29818,"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":910015,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-11T19:08:54.000Z","date":"2026-02-09","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":63.55,"value":794375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 6, 2025, and will terminate on August 31, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."}],"balance_after":31818,"source":{"system":"sec-edgar","filing":"0001711279-26-000011","document":"wk-form4_1770854928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000171127926000011/wk-form4_1770854928.xml","form_type":"4"}},{"id":1238657,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-28","kind":"grant","planned":true,"acquired":true,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F12","text":"The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The RSUs vest in four equal annual installments with the first installment vesting on February 28, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"The RSUs vest in four equal annual installments with the first installment vesting on February 28, 2026."}],"balance_after":2200,"derivative":{"underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1238656,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-28","kind":"grant","planned":true,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests in four equal annual installments beginning on February 28, 2026."}],"balance_after":10000,"derivative":{"exercise_price":179.25,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1238655,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Performance Stock Units","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-28","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"15,000 PSUs were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"15,000 PSUs were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"15,000 PSUs were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2025."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1238654,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Performance Stock Units","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-28","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"10,000 performance stock units (\"PSUs\") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024, and the remaining 5,000 PSUs vested on February 28, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"10,000 performance stock units (\"PSUs\") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024, and the remaining 5,000 PSUs vested on February 28, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"10,000 performance stock units (\"PSUs\") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024, and the remaining 5,000 PSUs vested on February 28, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1238653,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-28","kind":"tax_withholding","planned":true,"acquired":false,"shares":3471,"price":179.25,"value":622176.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 PSUs on February 28, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The closing price on February 28, 2025 of the Company's common stock on the Nasdaq Global Select Market."}],"balance_after":19318,"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1238652,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-28","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"15,000 PSUs were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2025."}],"balance_after":22789,"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1238651,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-28","kind":"tax_withholding","planned":true,"acquired":false,"shares":2315,"price":179.25,"value":414963.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 5,000 PSUs on February 28, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The closing price on February 28, 2025 of the Company's common stock on the Nasdaq Global Select Market."}],"balance_after":15289,"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1238650,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-28","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"10,000 performance stock units (\"PSUs\") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024, and the remaining 5,000 PSUs vested on February 28, 2025."}],"balance_after":17604,"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1238649,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-27","kind":"sale","planned":true,"acquired":false,"shares":750,"price":175.22,"value":131415.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The sale of the shares of the Company's common stock reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 18, 2024 and will terminate on the earlier of August 20, 2025 or the date all trades are executed or expire under the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple lots at the same price, $175.22."}],"balance_after":12604,"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1238648,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-28T19:01:45.000Z","date":"2025-02-26","kind":"tax_withholding","planned":true,"acquired":false,"shares":2268,"price":176.39,"value":400052.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2025. 19,600 Restricted Stock Awards (\"RSAs) were granted on February 26, 2021, to the Reporting Person. Each RSA represented a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSAs vested in four equal annual installments beginning on February 26, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The closing price on February 26, 2025 of the Company's common stock on the Nasdaq Global Select Market."}],"balance_after":13354,"source":{"system":"sec-edgar","filing":"0001801385-25-000002","document":"wk-form4_1740787298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138525000002/wk-form4_1740787298.xml","form_type":"4"}},{"id":1607327,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Performance Stock Units","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-29","kind":"grant","planned":true,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F15","text":"Each PSU represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement."},{"field":"shares","element":"transactionShares","label":"F16","text":"The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the performance criteria set by the Company's Compensation Committee for this PSU award and full vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"If any applicable portion of the performance criteria have been achieved, the PSU award shall vest in two equal annual installments (February 28, 2025 and February 28, 2026)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F18","text":"If some or all of the performance criteria are not achieved, the applicable portion of the PSU award will be forfeited."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607326,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Performance Stock Units","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F13","text":"Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The Performance Stock Units vest ratably over a two-year period with the first installment vesting on February 28, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F14","text":"The Performance Stock Units vest ratably over a two-year period with the first installment vesting on February 28, 2024."}],"balance_after":5000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607325,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"50,000 options were granted that vest in four equal annual installments with the first installment vesting on February 28, 2023."}],"balance_after":25000,"derivative":{"exercise_price":63.55,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607324,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"tax_withholding","planned":true,"acquired":false,"shares":2314,"price":163.08,"value":377367.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 5,000 PSUs on February 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The closing price on February 28, 2024 of the Company's common stock on NASDAQ."}],"balance_after":15622,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607323,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"10,000 performance stock units (\"PSUs\") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31\n2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or\n5,000 PSUs, vested on February 28, 2024."}],"balance_after":17936,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607322,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":90,"price":172.23,"value":15500.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607321,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":90,"price":63.55,"value":5719.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."}],"balance_after":13026,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607320,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":117,"price":169.8205,"value":19868.9985,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The transaction was executed in multiple trades ranging from $169.790 to  $170.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide\nupon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607319,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":117,"price":63.55,"value":7435.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."}],"balance_after":13053,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607318,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":1216,"price":169.0946,"value":205619.0336,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades ranging from $168.680 to  $169.610. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide\nupon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607317,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":1216,"price":63.55,"value":77276.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."}],"balance_after":14152,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607316,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":300,"price":167.85,"value":50355.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades ranging from$167.540 to $168.010. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide\nupon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607315,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":300,"price":63.55,"value":19065.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."}],"balance_after":13236,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607314,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":300,"price":166.0633,"value":49818.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $165.980 to $166.110. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide\nupon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607313,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":300,"price":63.55,"value":19065.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."}],"balance_after":13236,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607312,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":1429,"price":164.8075,"value":235509.9175,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $164.300 to $165.220. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide\nupon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607311,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":1429,"price":63.55,"value":90812.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."}],"balance_after":14365,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607310,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":900,"price":163.6756,"value":147308.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades ranging from $163.190 to  $164.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide\nupon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607309,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":900,"price":63.55,"value":57195.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."}],"balance_after":13836,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607308,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":648,"price":162.7102,"value":105436.2096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $162.155 to  $163.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide\nupon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607307,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:20:02.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":648,"price":63.55,"value":41180.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share."}],"balance_after":13584,"source":{"system":"sec-edgar","filing":"0001801385-24-000011","document":"wk-form4_1709342394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000011/wk-form4_1709342394.xml","form_type":"4"}},{"id":1607306,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"50,000 options were granted that vest in four equal annual installments with the first installment vesting on February 28, 2023."}],"balance_after":30000,"derivative":{"exercise_price":63.55,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607305,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"50,000 options were granted that vest in four equal annual installments with the first installment vesting on February 28, 2023."}],"balance_after":35000,"derivative":{"exercise_price":63.55,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607304,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":134,"price":171.6554,"value":23001.8236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The transaction was executed in multiple trades ranging from $171.460 to  $172.230. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607303,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":134,"price":63.55,"value":8515.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."}],"balance_after":13070,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607302,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":210,"price":169.751,"value":35647.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The transaction was executed in multiple trades ranging from $169.690 to $169.970. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607301,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":210,"price":63.55,"value":13345.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."}],"balance_after":13146,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607300,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":1133,"price":169.095,"value":191584.635,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The transaction was executed in multiple trades ranging from $168.680 to  $169.500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607299,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":1133,"price":63.55,"value":72002.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."}],"balance_after":14069,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607298,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":300,"price":167.85,"value":50355.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The transaction was executed in multiple trades ranging from $167.540 to $168.010. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607297,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":300,"price":63.55,"value":19065.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."}],"balance_after":13236,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607296,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":200,"price":166.04,"value":33208.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The transaction was executed in multiple trades ranging from $165.980 to $166.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607295,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":63.55,"value":12710.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."}],"balance_after":13136,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607294,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":164.8444,"value":263751.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The transaction was executed in multiple trades ranging from $164.360 to $165.270. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607293,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":1600,"price":63.55,"value":101680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."}],"balance_after":14536,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607292,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":786,"price":163.4937,"value":128506.0482,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The transaction was executed in multiple trades ranging from $163.120 to $164.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607291,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":786,"price":63.55,"value":49950.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."}],"balance_after":13722,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607290,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":637,"price":162.7254,"value":103656.0798,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The transaction was executed in multiple trades ranging from $162.115 to $163.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607289,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":637,"price":63.55,"value":40481.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share."}],"balance_after":13573,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607288,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":100,"price":171.45,"value":17145.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607287,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":100,"price":63.55,"value":6355.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."}],"balance_after":13036,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607286,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":203,"price":169.468,"value":34402.004,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades ranging from $169.345 to $170.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607285,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":203,"price":63.55,"value":12900.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."}],"balance_after":13139,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607284,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":700,"price":168.9136,"value":118239.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $168.275 to $169.190. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607283,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":700,"price":63.55,"value":44485.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."}],"balance_after":13636,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607282,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":100,"price":166.215,"value":16621.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607281,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":100,"price":63.55,"value":6355.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."}],"balance_after":13036,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607280,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":130,"price":165.2197,"value":21478.561,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $165.050 to $165.270. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607279,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":130,"price":63.55,"value":8261.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."}],"balance_after":13066,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607278,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":744,"price":164.6031,"value":122464.7064,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades ranging from $164.030 to $164.960. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607277,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":744,"price":63.55,"value":47281.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."}],"balance_after":13680,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607276,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":523,"price":163.134,"value":85319.082,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $162.825 to $163.820. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide\nupon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1607275,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-01T20:16:38.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":523,"price":63.55,"value":33236.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share."}],"balance_after":13459,"source":{"system":"sec-edgar","filing":"0001801385-24-000009","document":"wk-form4_1709342189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000009/wk-form4_1709342189.xml","form_type":"4"}},{"id":1612491,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T21:33:56.000Z","date":"2024-02-27","kind":"exercise","planned":true,"acquired":false,"shares":1913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and holding 1,913 shares with a prior closing price from $135.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"50,000 options were granted that vest in four equal annual installments beginning on January 20, 2021."}],"balance_after":0,"derivative":{"exercise_price":52.26,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":1913},"source":{"system":"sec-edgar","filing":"0001801385-24-000007","document":"wk-form4_1709174024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000007/wk-form4_1709174024.xml","form_type":"4"}},{"id":1612490,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T21:33:56.000Z","date":"2024-02-26","kind":"exercise","planned":true,"acquired":false,"shares":3087,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 3,087 shares with a limit price of $140.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"50,000 options were granted that vest in four equal annual installments beginning on January 20, 2021."}],"balance_after":1913,"derivative":{"exercise_price":52.26,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":3087},"source":{"system":"sec-edgar","filing":"0001801385-24-000007","document":"wk-form4_1709174024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000007/wk-form4_1709174024.xml","form_type":"4"}},{"id":1612489,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T21:33:56.000Z","date":"2024-02-26","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $135.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"50,000 options were granted that vest in four equal annual installments beginning on January 20, 2021."}],"balance_after":5000,"derivative":{"exercise_price":52.26,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001801385-24-000007","document":"wk-form4_1709174024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000007/wk-form4_1709174024.xml","form_type":"4"}},{"id":1612488,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-28T21:33:56.000Z","date":"2024-02-27","kind":"exercise","planned":true,"acquired":true,"shares":1913,"price":52.26,"value":99973.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and holding 1,913 shares with a prior closing price from $135.00 per share."}],"balance_after":12936,"source":{"system":"sec-edgar","filing":"0001801385-24-000007","document":"wk-form4_1709174024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000007/wk-form4_1709174024.xml","form_type":"4"}},{"id":1612487,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-28T21:33:56.000Z","date":"2024-02-26","kind":"tax_withholding","planned":true,"acquired":false,"shares":1533,"price":157,"value":240681.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The closing price on February 26, 2024 of the Company's common stock on NASDAQ."}],"balance_after":11023,"source":{"system":"sec-edgar","filing":"0001801385-24-000007","document":"wk-form4_1709174024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000007/wk-form4_1709174024.xml","form_type":"4"}},{"id":1612486,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-28T21:33:56.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":3087,"price":140,"value":432180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 3,087 shares with a limit price of $140.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at the same sale price."}],"balance_after":12556,"source":{"system":"sec-edgar","filing":"0001801385-24-000007","document":"wk-form4_1709174024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000007/wk-form4_1709174024.xml","form_type":"4"}},{"id":1612485,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-28T21:33:56.000Z","date":"2024-02-26","kind":"exercise","planned":true,"acquired":true,"shares":3087,"price":52.26,"value":161326.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 3,087 shares with a limit price of $140.00 per share."}],"balance_after":15643,"source":{"system":"sec-edgar","filing":"0001801385-24-000007","document":"wk-form4_1709174024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000007/wk-form4_1709174024.xml","form_type":"4"}},{"id":1612484,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-28T21:33:56.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":135,"value":675000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $135.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at the same sale price."}],"balance_after":12556,"source":{"system":"sec-edgar","filing":"0001801385-24-000007","document":"wk-form4_1709174024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000007/wk-form4_1709174024.xml","form_type":"4"}},{"id":1612483,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"ROMANO KATHRYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-28T21:33:56.000Z","date":"2024-02-26","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.26,"value":261300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $135.00 per share."}],"balance_after":17556,"source":{"system":"sec-edgar","filing":"0001801385-24-000007","document":"wk-form4_1709174024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000007/wk-form4_1709174024.xml","form_type":"4"}},{"id":1672148,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"Romano Kathryn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T17:44:40.000Z","date":"2024-01-22","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $130.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50,000 options were granted that vest in four equal annual installments beginning on January 20, 2021."}],"balance_after":10000,"derivative":{"exercise_price":52.26,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001801385-24-000002","document":"wk-form4_1706136270.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000002/wk-form4_1706136270.xml","form_type":"4"}},{"id":1672147,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"Romano Kathryn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-01-24T17:44:40.000Z","date":"2024-01-22","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":130,"value":325000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $130.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in one trade."}],"balance_after":12556,"source":{"system":"sec-edgar","filing":"0001801385-24-000002","document":"wk-form4_1706136270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000002/wk-form4_1706136270.xml","form_type":"4"}},{"id":1672146,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"Romano Kathryn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-01-24T17:44:40.000Z","date":"2024-01-22","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":52.26,"value":130650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $130.00 per share."}],"balance_after":15056,"source":{"system":"sec-edgar","filing":"0001801385-24-000002","document":"wk-form4_1706136270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138524000002/wk-form4_1706136270.xml","form_type":"4"}},{"id":1881211,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"Romano Kathryn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-23T16:23:20.000Z","date":"2023-05-22","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023."}],"balance_after":37500,"derivative":{"exercise_price":63.55,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001801385-23-000004","document":"wf-form4_168487338437565.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138523000004/wf-form4_168487338437565.xml","form_type":"4"}},{"id":1881210,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"Romano Kathryn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-23T16:23:20.000Z","date":"2023-05-22","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021."}],"balance_after":12500,"derivative":{"exercise_price":52.26,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001801385-23-000004","document":"wf-form4_168487338437565.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138523000004/wf-form4_168487338437565.xml","form_type":"4"}},{"id":1881209,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"Romano Kathryn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-23T16:23:20.000Z","date":"2023-05-19","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021."}],"balance_after":25000,"derivative":{"exercise_price":52.26,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001801385-23-000004","document":"wf-form4_168487338437565.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138523000004/wf-form4_168487338437565.xml","form_type":"4"}},{"id":1881208,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"Romano Kathryn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-23T16:23:20.000Z","date":"2023-05-19","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021."}],"balance_after":37500,"derivative":{"exercise_price":52.26,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001801385-23-000004","document":"wf-form4_168487338437565.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138523000004/wf-form4_168487338437565.xml","form_type":"4"}},{"id":1881207,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"Romano Kathryn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-05-23T16:23:20.000Z","date":"2023-05-22","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":110,"value":1375000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The transaction was executed in a single trade."}],"balance_after":12556,"source":{"system":"sec-edgar","filing":"0001801385-23-000004","document":"wf-form4_168487338437565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138523000004/wf-form4_168487338437565.xml","form_type":"4"}},{"id":1881206,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63347,"kind":"person","name":"ROMANO KATHRYN","position":1,"cik":"0001801385","reported_name":"Romano Kathryn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-05-23T16:23:20.000Z","date":"2023-05-22","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":63.55,"value":794375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share."}],"balance_after":25056,"source":{"system":"sec-edgar","filing":"0001801385-23-000004","document":"wf-form4_168487338437565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1801385/000180138523000004/wf-form4_168487338437565.xml","form_type":"4"}}],"next_cursor":"2023-05-23T16:23:20.000000Z,1881206"}